Design of an Optimized Wilms’ Tumor 1 (WT1) mRNA Construct for Enhanced WT1 Expression and Improved Immunogenicity In Vitro and In Vivo
Open Access
- 1 January 2013
- journal article
- research article
- Published by Elsevier in Molecular Therapy Nucleic Acids
- Vol. 2 (11) , e134
Abstract
No abstract availableKeywords
This publication has 50 references indexed in Scilit:
- Characterization of CD8+T-Cell Responses in the Peripheral Blood and Skin Injection Sites of Melanoma Patients Treated with mRNA Electroporated Autologous Dendritic Cells (TriMixDC-MEL)BioMed Research International, 2013
- Trial watchOncoImmunology, 2012
- Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemiaLeukemia, 2012
- Dendritic Cells Loaded With mRNA Encoding Full-length Tumor Antigens Prime CD4+ and CD8+ T Cells in Melanoma PatientsMolecular Therapy, 2012
- Active Specific Immunotherapy Targeting the Wilms' Tumor Protein 1 (WT1) for Patients with Hematological Malignancies and Solid Tumors: Lessons from Early Clinical TrialsThe Oncologist, 2012
- Major source of antigenic peptides for the MHC class I pathway is produced during the pioneer round of mRNA translationProceedings of the National Academy of Sciences, 2011
- Multiparameter RNA and Codon Optimization: A Standardized Tool to Assess and Enhance Autologous Mammalian Gene ExpressionPLOS ONE, 2011
- Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccinationProceedings of the National Academy of Sciences, 2010
- Proteases in MHC Class I Presentation and Cross-PresentationThe Journal of Immunology, 2009
- The Wilms' tumour protein (WT1) shuttles between nucleus and cytoplasm and is present in functional polysomesHuman Molecular Genetics, 2003